Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Infection with HCV
Must have participated in a prior Gilead HCV study
Use of highly effective contraception methods if female of childbearing potential or sexually active male
Eligible patients include those in the following
* received placebo or Peg-IFN+RBV in a control arm
* previously participated in a Gilead-sponsored HCV study and did not attain sustained virologic response 24 weeks after discontinuation of therapy (SVR24) on a regimen containing:
* Sofosbuvir+RBV
* Peg-IFN and/or RBV in combination with one or more Gilead investigational direct-acting agents
You may not be if
Pregnant or nursing female or male with pregnant female partner
Current or prior history of clinical hepatic decompensation
Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)
Chronic use of systemically administered immunosuppressive agents
Active drug abuse
Use of any prohibited concomitant medications
Clareo Health | Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
